Kunshi Bio: Clinical study of JS005 in the treatment of severe plaque psoriasis stage III has achieved positive results.

Junshi Biological announced that the recombinant humanized anti-IL-17A monoclonal antibody JS005 has achieved positive results in Phase III clinical studies for the treatment of severe plaque psoriasis. The study was led by Professor Zhang Jianzhong from Peking University People's Hospital and conducted in collaboration with 60 research centers nationwide. The main goal of the study was to compare the proportion of participants who achieved at least 90% improvement in psoriasis area and severity index compared to baseline at week 12, with a static physician global assessment score of 0 or 1, between the JS005 group and the placebo group. The results showed that JS005 significantly improved psoriasis lesion area and severity compared to placebo, with a significantly higher proportion of participants achieving an sPGA score of 0 or 1. The safety of JS005 was also good in participants with moderate to severe plaque psoriasis. The company plans to submit a marketing authorization application for this product to regulatory authorities in the near future.